Peer-influenced content. Sources you trust. No registration required. This is HCN.
OBR Oncology
Zev Wainberg, MD, professor of medicine and co-director of the UCLA GI Oncology Program at the University of California, Los Angeles, presented the results of the NAPOLI-3 trial at the ASCO Gastrointestinal Cancers Symposium last month, and in this podcast, he discusses the data with Bob Figlin, MD, the Steven Spielberg Family Chair in Hematology-Oncology at Cedars-Sinai Cancer. In addition, the physicians discuss what advances might be on the horizon in the metastatic setting and in earlier disease, as well as what factors influence Dr. Wainberg’s treatment decisions.
Oncology, Medical March 13th 2023
Mount Sinai
A look into the results of a few patients that took part in a phase 1/2 trial at the Icahn School of Medicine at Mount Sinai in New York City: a woman who had breast cancer for 23 years and gone through 12 lines of therapy and a man with non-Hodgkin lymphoma (NHL) since 2017. Both showed complete response to the novel vaccine.
JAMA Network
There were significant state variations in racial and ethnic disparities in TNBC incidence in this cohort study, with Black women in Delaware, Missouri, Louisiana, and Mississippi having the highest rates among all states and racial and ethnic populations. More research is needed to identify factors contributing to the significant geographic variations in racial and ethnic disparities in TNBC incidence in order to develop effective preventive measures, and social determinants of health contribute to the geographic disparities in TNBC risk, according to the findings.
Oncology, Medical March 6th 2023
Clinical Oncology News
Data on patients with mismatch repair deficiency (MMRD) CRC, the majority of whom could not undergo surgery due to various health conditions unrelated to cancer, were presented at the 2023 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI). Instead of radiation therapy or chemotherapy, the patients received immunotherapy with checkpoint inhibitors. It should be noted that the patients were treated outside of clinical trials. The overall response rate in this patient group was 74%, with 57% of those who responded experiencing complete tumor regression. Some of the patients have been in complete remission for a year or more after their diagnoses. The data indicate that immunotherapy is an effective treatment for patients who are unable to undergo surgery for a variety of reasons, including advanced age or a variety of health issues.
Gastroenterology March 6th 2023
Charu Aggarwal, MD, MPH, of the University of Pennsylvania’s Abramson Cancer Center in Philadelphia, H. Jack West, MD, of the City of Hope Comprehensive Cancer Center in the Los Angeles area, and Devika Das, MD, of the University of Alabama at Birmingham discuss the distinction between uncommon EGFR mutations and sensitizing mutations, as well as the lack of data on how to treat these patients with tyrosine kinase inhibitors.
MDLinx
The first version of the test, launched in November 2022, assesses chromosomal copy number changes in blood, cerebrospinal fluid, and the aqueous humor of the eye to aid in the clinical diagnosis of patients with solid tumors, brain tumors, and retinoblastoma, respectively. The next version of the clinical assay, which will be available in about six months, will detect mutations and gene fusions.